abs80.txt	programmed	cell	death	1	(pd-1)	and	its	ligand	(pd-l1)	are	key	physiologicsuppressors	of	the	cytotoxic	immune	reaction		however	to	date	combinationof	pd1/pd-l1	expression	tumor-infiltrating	lymphocytes	(tils)	andantigen-presenting	cells	has	been	only	minimally	reported	in	breast	carcinoma	inparticular	relation	her2-positive	cases	goal	this	study	was	toevaluate	both	cellular	tumoral	pd-l1/pd1	distribution	inher2-positive	as	well	any	associations	with	clinical	outcome	usingconventional	chemotherapy	combined	her2	blocking	multicolorimmunohistochemical	multiplex	assays	simultaneously	demonstrating	pd1	pd-l1	andcd8	or	cd3	cd163	were	performed	on	tissue	microarrays	(tma)representing	216	pretreatment	invasive	identified	38	(18%)	including	12	(6%)	withpd-l1	labeling	tumor	26	(12%)	immunecells	ten	staining	showed	ofassociated	assay	method	detectable	inmany	fewer	(6	3%)	positively	associated	withhigh	nottingham	grade	negative	er	pr	absence	lymph	node	metastasis	high	levels	cd8+	overall	survival	by	univariate	analysis	waspositively	lower	stage	nodemetastasis	therefore	our	datasuggest	mediated	cd8-positive	t	pd-l1expression	may	predict	a	better	patients	breastcarcinoma	managed	conventional	her2-blocking	therapy	thesefindings	recommend	trials	utilizing	checkpoint	immunotherapy	insome	form	for	cancer
